Sathishkumar Venkatachalam, Lokeshkumar Boobathi, Maruthaiveeran Periyasamy Balasubramanian.
Sathishkumar Venkatachalam, Lokeshkumar Boobathi, Maruthaiveeran Periyasamy Balasubramanian*
Department of Pharmacology and Environmental Toxicology, Dr. A.L. Mudhaliar Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600113, Tamilnadu, India
Volume - 6,
Issue - 3,
Year - 2014
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn’s disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. Drug delivery to the appropriate site(s) along the gastrointestinal tract also has been a major challenge, and second-generation agents have been developed with improved drug delivery, increased efficacy, and decreased side effect The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the, symptoms, diagnosis and current treatments for inflammatory bowel disease.
Cite this article:
Sathishkumar Venkatachalam, Lokeshkumar Boobathi, Maruthaiveeran Periyasamy Balasubramanian. Salubrious Therapeutic efficacy of Myrtenal on Colon Carcinoma induced by 1, 2-Dimethylhydrazine studied in experimental albino rats. Research Journal of Pharmacology and Pharmacodynamics. 2014; 6(3): 146-152.